Yes we eagerly await in anticipation for news of clinical benefits that may be attributed to the use of MPL for trial participants. Will it deliver similar to the dogs, improved QoL and survival. Certainly Prof. Mathers was not giving much away with her comments, “All of the participants have tolerated the study drug very well with no safety issues, despite a year of treatment. As investigators, we are very grateful for the enthusiastic support and commitment from our patients and their families. Like them, we eagerly await the study results.” Like she had a gun held to her head, but still nice to hear from her.
Yes we eagerly await in anticipation for news of clinical...
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.5¢ | $210.6K | 1.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 274938 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 15000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |